Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Immunology 8: Humoral and Cellular Therapy

PGG-Betafectin, a soluble β(1,3: 1,6) glucan, is processed by macrophages into an active moiety capable of priming neutrophil CR3 (CD11b) for cytotoxicity against iC3b- and monoclonal antibody-opsonized tumors

Daniel J. Allendorf, Richard D. Hansen, Jose L. Marroquin, Bing Li, Gordon D. Ross and Jun Yan
Daniel J. Allendorf
University of Louisville, Louisville, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard D. Hansen
University of Louisville, Louisville, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose L. Marroquin
University of Louisville, Louisville, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bing Li
University of Louisville, Louisville, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon D. Ross
University of Louisville, Louisville, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Yan
University of Louisville, Louisville, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

4269

The cellular and molecular mechanisms of action of β-glucans with anti-tumor activity have remained elusive. β-glucans belong to the family of biological response modifiers and have existed for centuries in Asian folk medicine and have been used clinically for decades, particularly in Japan, for cancer treatment. Previous studies from this lab indicated that β-glucans derived from yeast, mushroom, and barley prime neutrophils (PMNs) for cytotoxicity against iC3b-opsonized tumors as a result of complement activation by anti-tumor monoclonal antibodies (mAb). Specifically, whole β(1,3; 1,6) glucan particles (WGP) derived from saccharomyces cerevisiae (s. cerevisiae) that were fed to mice were shuttled by gastrointestinal macrophages (Mφ) to the bone marrow and spleen where they were degraded into smaller soluble fragments that primed PMN complement receptor 3 (CR3, CD11b/CD18, αmβ2 integrin, Mac-1) for cytotoxicity against iC3b-opsonized tumors. The present study demonstrates the in vivo efficacy, in combination with anti-tumor mAb, and describes the mechanism of action of PGG-Betafectin, a soluble β(1,3; 1,6) glucan polymer also purified from s. cerevisiae. Intravenous (i.v.) administration of PGG-Betafectin demonstrated anti-tumor activity in combination with anti-tumor mAb in implantable syngeneic and xenograft tumor models. Murine lymphoma RMAS cells engineered with human MUC1 were implanted in wildtype C57Bl/6 mice. Tumor bearing mice treated with PGG-Betafectin and anti-MUC1 mAb BCP8 achieved significant therapeutic efficacy compared to mice treated with PGG-Betafectin or mAb alone. Similar anti-tumor activity was observed in SCID mice challenged with Her2/neu positive human SKOV-3 ovarian carcinoma treated with PGG-Betafectin in conjunction with Herceptin. In addition, PGG-Betafectin, molecular weight of 150 kD, was added to a murine Mφ (J774.1 cells) culture, and by 7 days was processed by Mφ to a 25 kD fragment as determined by size-exclusion HPLC with a Sephacryl S-200 HR column. Subsequent experiments showed that the 25 kD fraction, but not the 150 kD parent, exhibited biological activities including direct binding to human PMNs as well as induction of the activation epitope of human CR3 (CD11b) lectin-like domain (LLD) as detected by the CBRM1/5 mAb. Lastly, the 25 kD fraction, but not the 150 kD parent, primed PMNs for anti-tumor activity in in vitro cytotoxicity assays. Thus, i.v. administered yeast-derived pharmaceutical-grade PGG-Betafectin is processed by Mφ, in an analogous manner to WGP, yielding a smaller active moiety of β-glucan that is able to prime PMN CR3 for cytotoxicity against iC3b- and mAb-opsonized tumors (Support: RO1 CA 86412, DAMD17-02-01-0445, Kentucky Lung Cancer Research Program, and Research Gift Funds from Biopolymer Engineering, Inc.)

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
PGG-Betafectin, a soluble β(1,3: 1,6) glucan, is processed by macrophages into an active moiety capable of priming neutrophil CR3 (CD11b) for cytotoxicity against iC3b- and monoclonal antibody-opsonized tumors
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
PGG-Betafectin, a soluble β(1,3: 1,6) glucan, is processed by macrophages into an active moiety capable of priming neutrophil CR3 (CD11b) for cytotoxicity against iC3b- and monoclonal antibody-opsonized tumors
Daniel J. Allendorf, Richard D. Hansen, Jose L. Marroquin, Bing Li, Gordon D. Ross and Jun Yan
Cancer Res May 1 2005 (65) (9 Supplement) 1008;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PGG-Betafectin, a soluble β(1,3: 1,6) glucan, is processed by macrophages into an active moiety capable of priming neutrophil CR3 (CD11b) for cytotoxicity against iC3b- and monoclonal antibody-opsonized tumors
Daniel J. Allendorf, Richard D. Hansen, Jose L. Marroquin, Bing Li, Gordon D. Ross and Jun Yan
Cancer Res May 1 2005 (65) (9 Supplement) 1008;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific CTLs
  • Cytogenetic and DNA microarray analysis of human glioma cell models resistant to alloreactive cytotoxic T lymphocytes
  • Adoptive transfer of tumor-reactive TGF-β-insensitive CD8+ T cells: infiltration into tumor tissue and induction of apoptosis
Show more Immunology 8: Humoral and Cellular Therapy
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement